Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
Characteristic Gut Microbiota in PCOS-IR Patients and Its Association with Endocrine Features.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liang Wenyi, Yao Yanning, Ren Xinyang, Xue Anran, Cai Mengcheng, Yu Jin, Yu Chaoqin, Zhou Ling, Zhai DongXia
Аннотация
PURPOSE: The aim of this study is to explore the changes of gut microbiota, the metabolic characteristics and sex hormones in polycystic ovary syndrome with insulin resistance (PCOS-IR), and to clarify the role of gut microbiota in the occurrence of this condition.
METHODS: We established a rat model of PCOS-IR using dehydroepiandrosterone (DHEA) combined with a high-fat diet, and recruited patients who met the clinical diagnostic criteria for PCOS-IR. We measured metabolic parameters and sex hormone profiles, and analyzed gut microbiota characteristics via high-throughput 16S rRNA sequencing. We also conducted microbial transplantation experiments to verify the causal relationship between gut microbiota and PCOS-IR.
RESULTS: In PCOS-IR rats, we observed significant endocrine-metabolic disturbances and alterations in gut microbiota β-diversity, characterized by an enrichment of Fusobacterium. Transplantation of this dysbiotic microbiota to healthy rats reproduced key PCOS-IR features, confirming a causal role. In people with PCOS-IR, we found a distinct gut microbial profile compared to both healthy individuals and those with PCOS without IR, with Fusobacterium consistently identified as a key genus across species.
CONCLUSION: Our findings show that gut microbiota disturbance leads to endocrine and metabolic features resembling PCOS-IR. The gut microbiota, particularly Fusobacterium, could serve as a clinical marker and potential therapeutic target for people with PCOS-IR. This study provides mechanistic insights into how gut microbiota contributes to PCOS-IR pathogenesis.
METHODS: We established a rat model of PCOS-IR using dehydroepiandrosterone (DHEA) combined with a high-fat diet, and recruited patients who met the clinical diagnostic criteria for PCOS-IR. We measured metabolic parameters and sex hormone profiles, and analyzed gut microbiota characteristics via high-throughput 16S rRNA sequencing. We also conducted microbial transplantation experiments to verify the causal relationship between gut microbiota and PCOS-IR.
RESULTS: In PCOS-IR rats, we observed significant endocrine-metabolic disturbances and alterations in gut microbiota β-diversity, characterized by an enrichment of Fusobacterium. Transplantation of this dysbiotic microbiota to healthy rats reproduced key PCOS-IR features, confirming a causal role. In people with PCOS-IR, we found a distinct gut microbial profile compared to both healthy individuals and those with PCOS without IR, with Fusobacterium consistently identified as a key genus across species.
CONCLUSION: Our findings show that gut microbiota disturbance leads to endocrine and metabolic features resembling PCOS-IR. The gut microbiota, particularly Fusobacterium, could serve as a clinical marker and potential therapeutic target for people with PCOS-IR. This study provides mechanistic insights into how gut microbiota contributes to PCOS-IR pathogenesis.